ZA200303847B - Guanidine and amidine derivatives as factor XA inhibitors. - Google Patents

Guanidine and amidine derivatives as factor XA inhibitors. Download PDF

Info

Publication number
ZA200303847B
ZA200303847B ZA200303847A ZA200303847A ZA200303847B ZA 200303847 B ZA200303847 B ZA 200303847B ZA 200303847 A ZA200303847 A ZA 200303847A ZA 200303847 A ZA200303847 A ZA 200303847A ZA 200303847 B ZA200303847 B ZA 200303847B
Authority
ZA
South Africa
Prior art keywords
alkyl
another
unsubstituted
mono
trisubstituted independently
Prior art date
Application number
ZA200303847A
Other languages
English (en)
Inventor
Anuschirwan Peyman
David William Will
Uwe Gerlach
Marc Nazare
Gerhard Zoller
Hans-Peter Nestler
Hans Matter
Fahad L-Obeidi
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of ZA200303847B publication Critical patent/ZA200303847B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200303847A 2000-12-06 2003-05-19 Guanidine and amidine derivatives as factor XA inhibitors. ZA200303847B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00126750 2000-12-06

Publications (1)

Publication Number Publication Date
ZA200303847B true ZA200303847B (en) 2004-04-15

Family

ID=8170585

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200303847A ZA200303847B (en) 2000-12-06 2003-05-19 Guanidine and amidine derivatives as factor XA inhibitors.

Country Status (26)

Country Link
US (2) US20020173656A1 (cs)
EP (1) EP1345900B1 (cs)
JP (1) JP4274522B2 (cs)
KR (1) KR20040015036A (cs)
CN (1) CN1479722A (cs)
AR (1) AR033684A1 (cs)
AU (2) AU2002233206B2 (cs)
BR (1) BR0115938A (cs)
CA (1) CA2430518C (cs)
CZ (1) CZ20031554A3 (cs)
DE (1) DE60126143T2 (cs)
DK (1) DK1345900T3 (cs)
EE (1) EE200300192A (cs)
ES (1) ES2278798T3 (cs)
HR (1) HRP20030447A2 (cs)
HU (1) HUP0302604A3 (cs)
IL (2) IL156214A0 (cs)
MX (1) MXPA03004848A (cs)
NO (1) NO20032489L (cs)
NZ (1) NZ526269A (cs)
PL (1) PL362320A1 (cs)
PT (1) PT1345900E (cs)
RU (1) RU2003120070A (cs)
SK (1) SK6862003A3 (cs)
WO (1) WO2002046159A1 (cs)
ZA (1) ZA200303847B (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1546089A2 (en) * 2002-08-09 2005-06-29 TransTech Pharma Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
WO2005014532A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
AU2004263508A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
US8603481B2 (en) * 2003-10-10 2013-12-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for solid tumors
EP1725555B1 (en) 2004-03-08 2010-10-06 Prosidion Ltd. Pyrrolopyridine-2-carboxylic acid hydrazides as inhibitors of glycogen phosphorylase
EP1819332B1 (en) 2004-12-02 2009-03-11 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amides
DE102006048300A1 (de) 2006-01-26 2007-08-02 Hellstern, Peter, Prof. Dr.med. Inhibitoren des Blutgerinnungsfaktors Xa zur Verwendung als Antikoagulans
US20100222381A1 (en) 2009-02-27 2010-09-02 Hariprasad Vankayalapati Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
US8507640B2 (en) 2010-08-19 2013-08-13 International Business Machines Corporation Methods of ring opening polymerization and catalysts therefor
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
TW201920081A (zh) 2017-07-11 2019-06-01 美商維泰克斯製藥公司 作為鈉通道調節劑的羧醯胺
BR112020003725A2 (pt) 2017-10-06 2020-11-03 Forma Therapeutics, Inc. inibição da peptidase 30 específica de ubiquitina
JP7449242B2 (ja) 2018-05-17 2024-03-13 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的ペプチダーゼ30(usp30)阻害剤として有用な縮合二環化合物
MX2021002981A (es) 2018-10-05 2021-05-14 Forma Therapeutics Inc Pirrolinas fusionadas que actuan como inhibidores de la proteasa 30 especifica de la ubiquitina (usp30).

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201303B (cs) * 1990-07-05 1993-03-01 Hoffmann La Roche
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
ES2103181B1 (es) * 1994-08-01 1998-04-01 Menarini Lab Amidas naftalenicas con accion antagonista de los leucotrienos.
HUT76346A (en) * 1994-04-26 1997-08-28 Selectide Corp Factor xa inhibitors
US5792769A (en) * 1995-09-29 1998-08-11 3-Dimensional Pharmaceuticals, Inc. Guanidino protease inhibitors
GB9602166D0 (en) * 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
TW542822B (en) * 1997-01-17 2003-07-21 Ajinomoto Kk Benzamidine derivatives
US6417200B1 (en) * 1997-06-26 2002-07-09 Eli Lilly And Company Antithrombotic agents
PL344056A1 (en) 1998-03-23 2001-09-24 Aventis Pharm Prod Inc Piperididinyl and n-amidinopiperidinyl derivatives
US20020016339A1 (en) * 1998-03-23 2002-02-07 Klein Scott I. Piperididinyl and N-amidinopiperidinyl derivatives
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
KR20020047175A (ko) * 1999-09-17 2002-06-21 밀레니엄 파머슈티컬스 인코퍼레이티드 Xa 인자의 억제제

Also Published As

Publication number Publication date
US20020173656A1 (en) 2002-11-21
EP1345900A1 (en) 2003-09-24
HRP20030447A2 (en) 2005-04-30
EE200300192A (et) 2003-08-15
KR20040015036A (ko) 2004-02-18
AU2002233206B2 (en) 2006-06-22
NO20032489D0 (no) 2003-06-02
US7435747B2 (en) 2008-10-14
BR0115938A (pt) 2003-12-23
CN1479722A (zh) 2004-03-03
HUP0302604A2 (hu) 2003-11-28
IL156214A0 (en) 2003-12-23
PL362320A1 (en) 2004-10-18
WO2002046159A1 (en) 2002-06-13
EP1345900B1 (en) 2007-01-17
JP2004515492A (ja) 2004-05-27
AR033684A1 (es) 2004-01-07
RU2003120070A (ru) 2004-12-27
NO20032489L (no) 2003-07-25
CA2430518C (en) 2010-06-15
JP4274522B2 (ja) 2009-06-10
CA2430518A1 (en) 2002-06-13
US20050143419A1 (en) 2005-06-30
DE60126143D1 (de) 2007-03-08
NZ526269A (en) 2004-11-26
PT1345900E (pt) 2007-03-30
SK6862003A3 (en) 2004-02-03
CZ20031554A3 (cs) 2003-08-13
DE60126143T2 (de) 2007-11-15
MXPA03004848A (es) 2003-08-19
IL156214A (en) 2010-05-31
AU3320602A (en) 2002-06-18
DK1345900T3 (da) 2007-05-21
ES2278798T3 (es) 2007-08-16
HUP0302604A3 (en) 2005-09-28

Similar Documents

Publication Publication Date Title
ZA200303847B (en) Guanidine and amidine derivatives as factor XA inhibitors.
ZA200304094B (en) Oxybenzamides derivatives as factor xa inhibitors.
EP1133555B2 (de) Pharmazeutisches faktor vii-präparat
WO2003044014A8 (en) Indole-2-carboxamides as factor xa inhibitors
TW200505914A (en) Pyrazole-derivatives as factor Xa inhibitors
ZA200209018B (en) Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use.
KR100587434B1 (ko) 신규 화합물
TW200510400A (en) Indazole-derivatives as factor Xa inhibitors
JP2004534717A (ja) 因子Xaの活性を阻害する新規な化合物
ZA200404147B (en) Pyrrolidine-2-ones as factor Xa inhibitors.
CN103403018A (zh) 胰蛋白酶样丝氨酸蛋白酶抑制剂,它们的制备以及作为凝结因子IIa和Xa的选择性抑制剂的用途
AU2001264494B2 (en) A combination product comprising melagatran and a factor xa inhibitor
YU29702A (sh) N-gvanidinoalkilamidi, njihovo dobijanje, njihova primena i farmaceutski preparati koji ih obuhvataju
ZA200104770B (en) Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor XA activity).
IL171843A (en) TRIAZOLE DERIVATIVES AS FACTOR Xa INHIBITORS
JP3838680B2 (ja) 抗凝血物質に対する解毒剤として用いるのに適した医薬およびその使用
Eisenberg Role of new anticoagulants as adjunctive therapy during thrombolysis
WO2004050636A3 (en) IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
US20080051388A1 (en) Novel Compounds That Inhibit Factor Xa Activity
AU2001264495B2 (en) A combination product comprising melagatran and a factor viia inhibitor
Kwaan et al. Anticoagulant drugs: an update
RS20050856A (en) Benzimidazole-derivatives as facor xa inhibitors
UA86767C2 (ru) АЗАИНДОЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ ФАКТОРА Ха
WO2000078749A1 (en) Sulfonamide derivative as factor xa inhibitor
Meijers et al. New concepts in activation of the clotting cascade in sepsis